Key result
High triglycerides linked to ~66% higher odds of prostate cancer on biopsy.
Why the study?
The relationship between serum triglyceride levels and the incidence and characteristics of prostate cancer detected on biopsy was investigated.
Does hypertriglyceridemia increase the incidence of prostate cancer in patients undergoing prostatic biopsy?
Observational (n=905)
Does hypertriglyceridemia increase the incidence of prostate cancer in patients undergoing prostatic biopsy?
Odds Ratio: 1.66 (95% CI 1.21–2.29)
p-value: p=0.002
High serum triglyceride levels (≥150 mg/dL) are associated with a higher incidence of prostate cancer and more aggressive disease (Gleason score ≥8) in patients aged ≥60 years undergoing biopsy.
Hypothesis-generating association; should not yet alter biopsy risk assessment or prompt lipid-targeted interventions.
OBJECTIVE: • To investigate the relationship between serum triglyceride (TG) levels and the incidence and characteristics of prostate cancer detected on biopsy. PATIENTS AND METHODS: • We evaluated data from consecutive patients who underwent prostatic biopsy. Data analysed included age, total serum prostate-specific antigen (PSA) level, prostatic volume, body mass index (BMI), TG levels, and cholesterol-lowering medications. RESULTS: • We analysed data from 905 patients, including 528 (58.3%) with positive biopsy findings. • Using 150 mg/dL as the threshold point of TG levels, multivariate analysis yielded an adjusted odds ratio (OR) reflecting the association of higher TG levels with prostate cancer diagnosis of 1.66 (95% confidence interval (CI) 1.21-2.29, P = 0.002). • Pearson correlation coefficient analysis including age, PSA level, prostatic volume, BMI and TG, showed TG level significantly correlated with BMI (r = 0.185, P < 0.001). • In the analysis by age intervals (≤59, 60-69, and ≥70 years), the association between high TG levels and positive biopsy findings was enhanced in the age groups 60-69 and ≥70 years (OR 2.10, 95% CI 1.31-3.37, P = 0.002 and OR 1.91, 95% CI 1.03-3.53, P = 0.039, respectively), but not in the group aged ≤59 years. • In patients aged ≥60 years, high TG levels were statistically significantly associated with a Gleason score of ≥8. CONCLUSIONS: • High TG levels correlated well with a higher incidence of prostate cancer, especially in patients aged ≥60 years. • High TG levels were also associated with a Gleason score of ≥8 in this age group. • Our results suggest that elderly patients with high TG levels may be more vulnerable to the development of prostate cancer with an aggressive biology.
No takes yet. Share an insight, caveat, or question.
Hayashi et al. (2011) conducted an observational in Prostate cancer (n=905). High serum triglyceride levels (≥150 mg/dL) vs. Triglyceride levels <150 mg/dL was evaluated on Prostate cancer diagnosis on biopsy (OR 1.66, 95% CI 1.21-2.29, p=0.002). High serum triglyceride levels (≥150 mg/dL) were significantly associated with an increased odds of prostate cancer diagnosis on biopsy (OR 1.66; 95% CI 1.21-2.29; P=0.002).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: